RegenTec was established in 2001 and is based at BioCity Nottingham, UK. The company is a spin-off from Professor Kevin Shakesheff’s internationally renowned research team at the University of Nottingham.

In recent years, Professor Shakesheff has been awarded the Hanson Medal, Royal Pharmaceutical Society of Great Britain Conference Medal, and was named in the MIT Technology Review 2002 list of the World’s Top 100 Young Innovators. The company has been awarded prestigious grants under the BBSRC SBRI, Framework 6, DTI Technology Programme, Smart and the Wellcome Trust Translation award schemes.

The company is managed by a commercially experienced board of directors with broad pharmaceutical and biotech expertise. The scientific direction of the company is further supported by its Clinical Advisory Board.

Members of the Board

Prof Kevin Shakesheff [Scientific Director]

• Professor of Drug Delivery & Tissue Engineering, The University of Nottingham
• Attracted over £4m academic funding in the past five years
• Named by MIT 2002 as one of the top 100 young innovators worldwide

Dr Robin Quirk [Managing Director]

• Managed company since incorporation
• Extensive tissue engineering research experience.
• A registered pharmacist with industrial & healthcare experience

Mr Steve Jones FCMA [Finance Director & Company Secretary]

• Founder Director and FD/ Co Sec of FDAS Ltd
• Successful career in a variety of financial, commercial and general management roles in major corporations
• Founded Acer Business Support Ltd

Dr Nikin Patel [Director]

• CEO Molecular Profiles Ltd
• 10th in the Sunday Times 2003 Tech Track 100 list
• 3rd in the 2003 Deloitte Midlands Fast 50 list